GSKGlaxoSmithKlineSigning up patients
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Amyloidosis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 60 (planned)
- Started
- Jun 24, 2026
- Main results expected
- Jan 12, 2033
- Fully finished
- Jan 12, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall complete hematologic response (CHR) rate
Measured over: Up to approximately 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07224672 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC